Hep-C
Community Summit
Marseille 25-26 Nov 2019
Programme
PRACTICAL INFORMATION

Event venue
Center The Mistral
11 Impasse Flammarion
13001 Marseille

Hotel
Hotel ibis Marseille Centre Gare Saint Charles
Square Narvick, Espl. Saint-Charles, 13001 Marseille, Frankrijk
Telefoon: +33 4 91 95 62 09

Emergency contact
For any logistical issues or questions, please contact
Contact Linda Vermout 00 31 6 24 89 22 05

How to stay connected
Hashtag
#HCVsummit – join the conversation

Correlation Network social media
twitter.com/CorrelationNet
Facebook.com/correlation.network
Bridging the gap between research, harm reduction, treatment and people living with hepatitis C

Hepatitis C is an easy to treat disease also with people who use drugs and other key populations. Elimination is possible with the necessary political will. Harm reduction and community services play a crucial role in this setting.

The 3rd Hepatitis Community Summit will discuss these issues and brings together researcher, health and community workers, medical staff and HCV patients and advocates.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09.00 – 09.15 | **Welcome**  
Eberhard Schatz, C EHRN  
Carine Magen, Eurosider                                                                 |
| 09.15 – 10.45 | **Introduction**  
Chair: Eberhard Schatz  
Beatrice Stambul, Bus 31/32  
Harm reduction in Marseille: from the first steps to safe consumption (rooms)  
Joachim Levy, Nouvelle Aube  
Community Involvement makes the difference  
**Beyond HCV: Healthcare for all**  
Perrine Roux, INSERM  
Safe injection training saves life – experiences  
Fadi Meroueh, European Federation for Prison Health  
Health in prison settings  
Freek Spinnewijn, FEANTSA  
Health and homelessness  
Jean Paul Grund, (Stop Overdose Now)  
Overdose prevention in the 21st century |
| 10.45 – 11.15 | **Coffee Break**  |
| 11.15 – 12.30 | **Panel discussion: what is the influence of criminalisation to the health of people who use drugs?**  
Moderator: Graham Shaw  
Introduction to the subject: Marta Pinto, University of Porto  
Panel:  
Rui Coimbra Morais, EuroNPUD |  
Daniele Bader, former Head of the DCR Strasbourg and Member of the Conseil d’administration de l’ Association Ithaque |  
Victor Martin, Plus Belle la Nuit  
“Call of Marseille for another drug policy / Appel de Marseille pour une autre politique des drogues”  
Launch of the Hepatitis C Community Summit Statement |
| 12.30 – 14.00 | **Lunch**  
Incl. market place with booth and poster presentations |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Facilitator</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 – 15.30</td>
<td><strong>Workshops or abstract driven</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Parallel session 1</strong></td>
<td><strong>Facilitator:</strong> C EHRN, EMCDDA</td>
<td>What can we learn from existing good practices in harm reduction and community initiatives to tackle HCV.</td>
</tr>
<tr>
<td></td>
<td><strong>Models of good practice</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Parallel session 2</strong></td>
<td><strong>Facilitator:</strong> Coalition Plus</td>
<td>Key policy barriers and responses to HCV-related services in prisons.</td>
</tr>
<tr>
<td></td>
<td><strong>HCV in prison</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Parallel session 3</strong></td>
<td><strong>Facilitator:</strong> EuroNPUD</td>
<td>Encouraging examples and discussion</td>
</tr>
<tr>
<td></td>
<td><strong>Peer Involvement works – we just need to implement it</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Parallel session 4</strong></td>
<td><strong>Facilitator:</strong> Eurosider</td>
<td>Individually-tailored support and education for safer injection (ITSES) for people who inject drugs.</td>
</tr>
<tr>
<td></td>
<td><strong>Capacity building</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30 – 16.00</td>
<td><strong>Coffee Break</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.00 – 17.30</td>
<td><strong>Workshops or abstract driven</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Parallel session 5</strong></td>
<td><strong>Facilitator:</strong> EATG</td>
<td>Speakers from different countries will address the gap between treatment and people living with Hepatitis C.</td>
</tr>
<tr>
<td></td>
<td><strong>Access to services</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Parallel session 6</strong></td>
<td><strong>Facilitator:</strong> Stop Overdose Now</td>
<td>Presenting of the OD buster app and try out.</td>
</tr>
<tr>
<td></td>
<td><strong>ODBuster – Digitally Networking the Response to Opioid Overdose Emergencies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Parallel session 7</strong></td>
<td><strong>Facilitator:</strong> Africa Advocates</td>
<td>Encouraging examples and discussion.</td>
</tr>
<tr>
<td></td>
<td><strong>HCV prevention for (un) documented migrants</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Parallel session 8</strong></td>
<td><strong>Facilitator:</strong> Aides, Eurosider partners</td>
<td>Presentation and discussion of the Safe Use training</td>
</tr>
<tr>
<td></td>
<td><strong>Building Capacity to support People who use drugs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.30 – 18.30</td>
<td><strong>Reception</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21.00</td>
<td><strong>Conference Party (own costs) L'Intermediaire Live</strong></td>
<td></td>
<td>63 Place Jean Jaurès 13006 Marseille</td>
</tr>
<tr>
<td></td>
<td><strong>Conference Party (own costs) L'Intermediaire Live</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.00 – 10.30</td>
<td><strong>Elimination of HCV – where we stand today</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: <strong>Perrine Roux</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Antons Mozalevskis</strong>, WHO Europe - live stream</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>WHO elimination targets for 2030 and where we stand today</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dagmar Hedrich</strong>, EMCDDA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HepC Initiative and Elimination Barometer for PWID: new EMCDDA tools to support countries</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Leon Wylie</strong>, Hepatitis Scotland</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Scotland: On the road to elimination?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Hélène Délaqualze</strong>, SOS Hépatitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>From Chronic Disease to a Curable Disease: the fight of civil society in France to make treatment accessible</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Andrew Ustianowski</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Regional Infectious Diseases Unit, North Manchester General Hospital –</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Micro elimination in Manchester</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30 – 11.00</td>
<td><strong>Coffee Break</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00 – 12.30</td>
<td><strong>Flashlight on expertise:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: <strong>Marie dos Santos</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NGO’s, community members, HR workers share their experiences working with HCV and/or Overdose Prevention</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>‘Coming out for HCV – from personal story to policy’</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: <strong>Sebastian Saville</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Marios Atzemis</strong>, Positive Voice</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>George Lachaze</strong>, ASUD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Erin O’Mara</strong>, EuroNPUD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Theo van Dam</strong>, Dutch Drug User Activist</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>EuroNPUD award ceremony for drug user activism</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Final Wrap Up: what we can take home from the Meeting</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Andrew Ustianowksi</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
13.00

Lunch sandwich package Site visit (optional)

Guided tour through Marseille’s street culture and harm reduction sites (optional)

Premier itinéraire: Bus 31/32; C$APA Casanova; Nomades Célestes
Deuxième itinéraire: Sleep’In/Le Spot/Autre Regard

Troisième itinéraire: Santé!, Le Tipi, et addiction méditerranée au reformés (fil rouge, baïta, etc).
PARALLEL SESSIONS DETAILS

Parallel session 1 -
What can we learn from existing good practices in harm reduction and community initiatives?

Chair: Eberhard Schatz, C EHRN

In several recent projects and publications, the European Monitoring Centre for Drugs and Drug Addiction and Correlation-European Harm Reduction Network have been promoting effective ways for improving access to the hepatitis care cascade for people who use drugs (PWUD).

The publications describe different approaches such as the integration of hepatitis testing with harm reduction programmes; strategies of harm reduction programmes to strengthen linkage from testing to care and treatment; decentralized service provision, supported by task-sharing between harm reduction programmes and specialist providers of testing and/or treatment; the integration of hepatitis treatment at harm reduction programmes; and the involvement of peer support workers to reach vulnerable or disadvantaged communities.

- Eberhard Schatz – Harm reduction organisations in HCV testing and treatment. A survey in 33 countries in Europe.
- Dagmar Hedrich – Models of care for drug services in Europe. Case studies and analysis.
- Marie Francis, John Gibbons – Peer supported HCV models of care. Results from the HepCare project.
- Raquel Gloria – Comparison of two proximity-based models of care to increase HCV treatment adherence among people who use drugs in Lisbon.
- Jan Kozak – Harm reduction and integration to care: example Prague.
- F. Oster – Test and treat drug users in a consumption room in the area of DAA’s.

Discussion

Parallel session 2 -
Key policy barriers and responses to HCV-related services in prisons

Chair: Chase Perfect, Coalition Plus

The parallel session on prisons will focus on key policy barriers and responses to HCV-related services in prisons; it will share knowledge of actions and actors in this space; and it will discuss ways to reinforce networks and advocacy efforts working on this issue.

Criminalization of drug use contributes to high rates of detention and/or incarceration of PWUD. In addition to the high exposure to HCV-associated risks pre- or post-prison of PWUD, the lack of strong public health services in prison can itself further exacerbate those risks. While prisons introduce a broad range of health risks, the correlation of HCV and prison populations is particularly strong; in fact, global estimates suggest that the HCV in prison populations is nearly 5 times more prevalent than TB or HIV. In most countries, HCV elimination will not be feasible until national responses integrate comprehensive HCV services in prison settings. This includes harm reduction, sensitization, and HCV diagnosis/treatment.

- Rachel Halford (Executive Director of the Hepatitis C Trust) – From pilot intervention to scale up: the mobilization of peer-led approach to engagement in HCV services and the successful effort to push expansion of the model at national level
- Fadi Meroueh (Physician CHRU Montpellier, Vice President of Health without Borders) – the challenge of converting prison health systems from obstacle to catalyst of HCV elimination
- Telma Azevedo (Physician at Centro Hospitalar de Setúbal) – Infectious disease consults inside correctional facilities: the experience from a Portuguese Center
- Paschalis Vavelidis (Hellenic Liver Patients Association “Prometheus”) – Access4All : the first holistic intervention for HCV micro-elimination among people in Greek prisons
Parallel session 3 - 
Peer Involvement works – we just need to invest it

1. Welcome and introduction – Tonny van Montfort, Rui Coimbra Morais, EuroNPUD
2. Abstract driven session on examples of peer involvement and user advocacy from Norway, Switzerland, France, Slovenia, Greece and the United Kingdom.
3. Integrative moment: Mat Southwell
4. Small Group questions on Peer Involvement
5. Group debriefing with contributions to a document with a more comprehensive statement on this issue and with the contributions, insights and inputs from the session.

Speakers:
• Ole Jorgen – The Hepatitis Bus – a Norwegian drug user initiative moves on.
• Oliver Werzli – HEPFREE.ch – Peers make the difference to reach out.
• Joachim Levy – Early detection, screening and access to treatment, provided by user groups in Marseille squats and shelters.
• Janko Belin – Campaign Coordination experience.
• Christos Anastasiou – EuroNPUD country level direct support and the quick development of actions.

Parallel session 4 - 
Individually-tailored support and education for safer injection (ITSESI) for people who inject drugs

Chair: Caren Magen, Eurosider

We will show the effectiveness of the intervention on HIV-HCV risk practices and other complications among PWID and analyze the transferability of this harm reduction tool.

The Eurosider project is a transferability study to implement in 4 European countries an individually-tailored support and education for safer injection (ITSESI) for people who inject drugs. This community-based intervention has already been has shown its effectiveness in reducing HIV-HCV risk practices in France. INSERM (France), AIDES (France), Correlation Network (Hollande) take in charge the coordination. Praksis (Greece), ARAS (Romania), IHF (Bulgaria) and GAT (Portugal) implement the project on the field.

Methods: The project uses mixed methods and implementation science. It started with a first exploratory step using quantitative data of each local context chosen for the implementation of the ITSESI intervention and some qualitative interviews with key informers. The second phase consisted in implementing and evaluating this community-based educational intervention, starting with a training process in the selected contexts. For the evaluation phase, this study enrolled 300 PWID (75 per harm reduction centre or per country) seeking support for their injection practices and to provide them with the intervention.

Results: From the context assessment, the results showed that financing HR activities for people who inject drugs (PWID), especially the sustainability of Needle Syringes Exchange Program (NSP), has emerged as a determining factor for the feasibility of the implementation of ITSESI as well as the National Drug Policy.

The tools and methods of the training are contributing to guide the next steps with the observation of injection’s practice and the educational session.

Discussion: The results will show the effectiveness of the intervention on HIV-HCV risk practices and other complications among PWID and analyze the transferability of this harm reduction tool. It also demonstrates that ITSESI implementation in different contexts needs to gather material, technical skills and advocacy to ensure a favorable environment.
Parallel session 5 -
The gap between treatment and people living with Hepatitis C - barriers and opportunities

Chair: Marios Atzemis, Positive Voice, EATG

The session presents challenges and how to overcome them in treating marginalised groups in different settings

- Joana Correia Pires – The gap between treatment and people living with hepatitis C: a pilot study in a Community Centre in Lisbon.
- Simona Ciobanu – Developed for the community by the community: access to testing and treatment.
- Julian Surey – The HepCare peer intervention project: morbidity, mortality and linkage to care in a homeless population at risk of hepatitis C.

Parallel session 6 -
ODBuster – Digitally Networking the Response to Opioid Overdose Emergencies

Chair: Jean Paul Grund, Stop Overdose Now

WORKSHOP

STOP OVERDOSE NOW presents a suite of mobile tools to combat the opioid overdose epidemic that will empower people who use drugs to take action within their own community and when they travel.

Stop Overdose Now is developing a suite of Ecological Momentary Assessment and Intervention (EMAI) applications that take advantage of the best of mobile technologies to digitally empower the response to the opioid overdose epidemic.

The core application concerns OD Buster, a free community based overdose response networking app that connects naloxone carrying peers and other volunteers with people who use opioids in emergency situations. The app uses modern GPS, inferential positioning, and instant alerting to immediately notify and direct any nearby volunteers to the site of an overdose in progress.

In this workshop we will demonstrate the ODBuster app, discuss its present and future features, and engage the participants in a discussion on the possibilities for deploying it in community based overdose prevention interventions in their work.
Parallel session 7 -
HCV and (un) documented migrants access to health and HCV prevention

Chair: Denis Onyango, African Advocates

The session will highlight and discuss the work of harm reduction and community services for the target group of (un) documented migrants in particular in outreach settings.

- Denis Onyango – The role of community organisations to improve prevention and access to health for migrants
- Moro Yapha – Outreach, peer work and the challenge to prevent infection diseases under undocumented migrants at Görlitzer Park, Berlin
- Elias Phiri – HCV Screening in Migrant Communities in London Borough of Waltham Forest
- Marie Asensio – working with migrants in the streets of Marseille

Parallel session 8 -
Introduction to the Eurosider training: hands on experiences

Chair: Richard Stranz, Aides

Eurosider training Module : Building capacity to support PWID

After a brief introduction and overview of the content and results of the training work-package, this workshop will allow participants the chance to get a real feel of the content of the training. Trainers from the project will facilitate group work in English to highlight the method of the intervention. Using material from the training, the group work will be based on a case study, observations via video of an injection and identification of empowering, pertinent and key harm reduction messages.

Presentation and group work

The training work package overview and results

Hands on experience/ getting an idea of the training group works based on à case study and video.

- PART ONE: the pre injection interview
- PART TWO Observation of the injection viewing the video
- PART THREE : post injection interview

Conclusions
Programme Committee

Aides, Richard Stranz | Coalition Plus, Chase Perfect | C-EHRN, Eberhard Schatz
EATG, Marios Afzemis | EuroNPUD, Erin O’Mara | IDHDP, Sebastian Saville
INSERM, Perrine Roux, Caren Magan

Partners

Correlation Network receives funding from the European Union

Sponsors

The organizing committee would also like to extend a special thank to the sponsors of the 3rd Hepatitis-C Summit